Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN 3.9% rapamycin anhydrous gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania Show more
125 Strafford Avenue, Wayne, PA, 19087, United States
Market Cap
1.737B
52 Wk Range
$18.23 - $151.18
Previous Close
$122.06
Open
$124.08
Volume
315,340
Day Range
$123.93 - $134.40
Enterprise Value
1.673B
Cash
63.57M
Avg Qtr Burn
-7.878M
Insider Ownership
19.92%
Institutional Own.
80.66%
Qtr Updated
09/30/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
QTORIN Rapamycin Details Microcystic Lymphatic Malformations | NDA Submission | |
QTORIN Rapamycin Details Cutaneous Venous Malformations | Phase 2 Update | |
QTORIN Rapamycin Details Angiokeratomas | Phase 2 Initiation | |
QTORIN™ pitavastatin Details Disseminated superficial actinic porokeratosis (DSAP) | Phase 2 Initiation |
